Indinavir

Drug Profile

Indinavir

Alternative Names: Crixivan; Indinavir sulfate; L 735524; MK 639

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Banyu; M S Jacovides & Co; Merck & Co; Merck Sharp & Dohme
  • Class Antiretrovirals; Pyridines
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 05 Sep 2003 A case report has been added to the adverse events section
  • 23 Jul 2002 A case report has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top